Clinical Study Of Wenyang Qingchang Prescription In The Treatment Of Ulcerative Colitis

Objective:The purpose of this study was to observe the clinical efficacy and adverse reactions of Wenyang Qingchang recipe in the treatment of mild and moderate active ulcerative colitis of spleen and kidney yang deficiency,to objectively evaluate the efficacy and safety of this treatment,and to provide clinical basis and methodology for exploring the treatment of ulcerative colitis with traditional Chinese and western medicine。Method:In this study,60 patients with ulcerative colitis of spleen and kidney yang deficiency type who met the research criteria were randomly divided into treatment group and control group with 30 cases each according to the random number table allocation principle.In the treatment group,Wenyang Qingchang Decoction combined with mesalazine enteric-coated tablets were taken orally.Wenyang Qingchang Decoction was taken once a day with 200 ml of water,twice in the morning and evening on an empty stomach.Mesalazine enteric-coated tablets 1.0g twice a day.Patients in the control group took orally mesalazine enteric-coated tablets,2.0g each time,twice a day.The treatment period of both groups was12 weeks.After the treatment,the clinical symptom efficacy,colonoscopy efficacy and safety evaluation of the two treatment options were objectively evaluated.The relevant data collected by the research institute is processed,analyzed and compared using statistical software SPSS26.0.Result:Comprehensive efficacy: 1.In terms of clinical effectiveness,27 cases were clinically effective in the treatment group and 20 cases were clinically effective in the control group.The clinical effective rates of the treatment group and the control group were 93.10% and66.67%,respectively;P<0.05,there was a difference Statistical significance.2.In terms of clinical remission rate,there were 25 clinical remissions in the treatment group and 17 clinical remissions in the control group.The clinical effective rates of the treatment group and the control group were 86.20% and 56.67% respectively;P<0.05,the difference was statistically significant.In terms of the efficacy of TCM symptoms: 1.Comparison of the overall efficacy of TCM syndromes: After treatment,the effective rate of the treatment group reached 93.10%,and the effective rate of the control group was 73.33%,suggesting that the treatment group was better than the control group in improving TCM syndromes(P<0.05)).2.Comparison of individual scores of TCM syndromes: The individual symptoms of the two groups were compared within the group,P<0.05,the difference was statistically different,indicating that the two groups of drugs can improve the spleen and kidney yang deficiency syndrome.In comparison between the groups,the treatment group had better curative effect than the control group in terms of abdominal pain,bloating,poor appetite,cold limbs,and waist and knee weakness(P<0.05);in terms of other symptoms,the two groups had similar effects(P>0.05)).3.Comparison of total scores of TCM syndromes: before and after treatment,the two groups were compared within the group.P<0.05 after testing,the difference was statistically significant.After treatment,a comparison between the groups was carried out.The test P<0.05 indicated that both groups could improve the syndrome of spleen and kidney yang deficiency,but the therapeutic effect of the treatment group was better than the control group.In terms of the efficacy of colonoscopy: 1.Comparison of mucosal healing rate:re-examination of colonoscopy in the treatment group showed 18 cases of intestinal mucosal healing,and 10 cases of re-examination of intestinal mucosal healing in the control group.The mucosal healing rates of the treatment group and control group were 62.07%and 33.33%,respectively.Χ2 test was statistically significant(P<0.05),indicating that the mucosal healing rate of the treatment group was better than that of the control group.2.Comparison of colonoscopy treatment scores: within the group analysis,the rank sum test of the two groups before and after treatment(P<0.05),the difference was statistically significant.After the treatment,the comparison between the groups was carried out,and the test P<0.05 indicated that both groups can improve the spleen and kidney yang deficiency syndrome,but the therapeutic effect of the treatment group is better than that of the control group.Safety: During the clinical observation period,there were no obvious adverse reactions in the treatment group and the control group.There were no abnormalities in the safety tests of ECG,blood routine,urine routine,stool routine,liver and kidney function before and after treatment.Conclusion:The clinical efficacy of Wenyang Qingchang Decoction combined with mesalazine enteric-coated tablets in the treatment of mild to moderate ulcerative colitis in the active stage is better than that of mesalazine enteric-coated tablets alone.It is worthy of further clinical research and promotion.